YN 001
Alternative Names: YN-001Latest Information Update: 19 Oct 2023
At a glance
- Originator Beijing Inno Medicine
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 08 Oct 2023 Phase-I clinical trials in Atherosclerosis in China (IV, injection) (NCT05635084)
- 22 Sep 2023 Beijing Inno Medicine plans phase-I trial for Cardiovascular disorders in October 2023 (IV) (NCT06048588)
- 06 Dec 2022 Phase I clinical trials for Cardiovascular disorders (In volunteers) in Australia (IV) (NCT05635084)